Update: Acute Heart Failure (1)

Acute Heart Failure: Epidemiology, Risk Factors, and Prevention

Dimitrios Farmakis, John Parissis, John Lekakis, and Gerasimos Filippatos*

Heart Failure Unit, Department of Cardiology, Attikon University Hospital, Athens, Greece

Article history:
Available online 4 February 2015

Keywords:
Acute heart failure
Epidemiology
Risk factors
Prevention

ABSTRACT

Acute heart failure represents the first cause of hospitalization in elderly persons and is the main determinant of the huge healthcare expenditure related to heart failure. Despite therapeutic advances, the prognosis of acute heart failure is poor, with in-hospital mortality ranging from 4% to 7%, 60- to 90-day mortality ranging from 7% to 11%, and 60- to 90-day rehospitalization from 25% to 30%. Several factors including cardiovascular and noncardiovascular conditions as well as patient-related and iatrogenic factors may precipitate the rapid development or deterioration of signs and symptoms of heart failure, thus leading to an acute heart failure episode that usually requires patient hospitalization. The primary prevention of acute heart failure mainly concerns the prevention, early diagnosis, and treatment of cardiovascular risk factors and heart disease, including coronary artery disease, while the secondary prevention of a new episode of decompensation requires the optimization of heart failure therapy, patient education, and the development of an effective transition and follow-up plan.

© 2014 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Insuficiencia cardiaca aguda: epidemiología, factores de riesgo y prevención

RESUMEN

La insuficiencia cardiaca aguda constituye la primera causa de hospitalización en las personas ancianas y es el principal factor determinante del enorme gasto de asistencia sanitaria asociado a la insuficiencia cardiaca. A pesar de los avances terapéuticos realizados, la insuficiencia cardiaca aguda tiene un mal pronóstico, con una mortalidad hospitalaria que oscila entre el 4 y el 7%, una mortalidad a los 60 a 90 días de entre el 7 y el 11% y una tasa de rehospitalizaciones a los 60 a 90 días que va del 25 al 30%. Hay varios factores, entre los que se encuentran los trastornos cardiovasculares y no cardiovasculares, así como factores relacionados con el paciente y factores iatrogénicos, que pueden desencadenar una progresión rápida o un agravamiento de los signos y síntomas de insuficiencia cardiaca, lo que conduce a un episodio de insuficiencia cardiaca aguda que suele requerir el ingreso hospitalario del paciente. La prevención primaria de la insuficiencia cardiaca aguda se centra principalmente en la prevención, el diagnóstico precoz y el tratamiento de los factores de riesgo cardiovascular y la cardiopatía, incluida la enfermedad coronaria, mientras que la prevención secundaria para evitar nuevos episodios de descompensación requiere la optimización del tratamiento de la insuficiencia cardiaca, la educación sanitaria del paciente y el desarrollo de una transición y un plan de seguimiento efectivos.

© 2014 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Abbreviations

AHF: acute heart failure

* Corresponding author: Heart Failure Unit, Athens University Hospital, 12461 Athens, Greece. E-mail address: geros@otenet.gr (G. Filippatos).

INTRODUCTION

Acute heart failure (AHF) is the rapid development or change of signs and symptoms of heart failure that requires medical attention and usually leads to patient hospitalization.1–3 Acute heart failure represents the first cause of hospital admission in elderly persons in the western world and, despite advances in medical and device therapy, it still has unacceptably high morbidity and mortality rates. As a result, AHF represents a major public health issue, an enormous financial burden, and a challenge for current cardiovascular research.3
**EPIDEMIOLOGY**

A number of large-scale registries, such as the ADHERE\(^1\)-\(^6\) and OPTIMIZE-HF performed in the United States,\(^1\)-\(^7\) the EHFS I and II\(^8\)-\(^16\) and the ESC-HF Pilot registry performed in Europe,\(^8\)-\(^11\) as well as the international ALARM-HF\(^12\) have provided us with some epidemiological evidence on AHF.

Patients admitted for AHF are aged >70 years and about half of them are male. Most have a previous history a heart failure, while de novo AHF represents only one-fourth to one-third of cases. About 40% to 55% have preserved LVEF (left ventricular ejection fraction). Those patients have a constellation of cardiovascular and noncardiovascular abnormalities. Concerning cardiovascular comorbid conditions, most AHF patients have a history of arterial hypertension, about half have coronary artery disease, and one-third or more have atrial fibrillation. In terms of noncardiovascular comorbidities, about 40% of patients admitted for AHF have a history of diabetes mellitus, about one-fourth to one-third have renal dysfunction and chronic obstructive pulmonary disease, while anemia is also present in 15% to 30% of patients. The main clinical features of AHF patients according to the aforementioned registries are outlined in Table 1.

In most of the published AHF registries, in-hospital mortality ranges from 4% to 7% (Table 2), with the exception of ALARM-HF, in which mortality was as high as 11%, apparently due to the relatively higher proportion of patients with cardiogenic shock (around 12% vs <4% in the rest of the aforementioned registries). The median length of hospital stay ranged from 4 days to 11 days. Postdischarge mortality up to 3 months was 7% to 11%, while 1-year postdischarge mortality reported by the ADHERE registry was 36%.\(^4\) Heart failure progression itself represents the cause of death in less than half of patients. According to data from the EVEREST trial,\(^13\) 41% of AHF patients die of heart failure deterioration, 26% die suddenly, and 13% die of noncardiovascular comorbidities. It should be stressed that, although in-hospital mortality tends to be higher in patients with reduced LVEF compared with those with preserved LVEF, postdischarge morbidity is similar in the 2 groups.\(^14\)

Postdischarge rehospitalization rates are quite high, as about one-fourth of patients are readmitted within 3 months, while two-thirds of them are rehospitalized within a year. It has been shown that the readmission rate follows a biphasic course consisting of 2 peaks, an early one during the first 2 to 3 months postdischarge and a late one during the final stage of the syndrome, separated by a long plateau phase with low admission rates.\(^15\)

### Table 1
Clinical Characteristic of Acute Heart Failure Patients in Different Registries

<table>
<thead>
<tr>
<th></th>
<th>ADHERE</th>
<th>OPTIMIZE-HF</th>
<th>EHF S I</th>
<th>EHFS II</th>
<th>ESC-HF Pilot (AHF arm)</th>
<th>ALARM-HF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No.</td>
<td>105 388</td>
<td>48 612</td>
<td>11 327</td>
<td>3580</td>
<td>1892</td>
<td>4953</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>72.0 (14.0)</td>
<td>73.1 (14.2)</td>
<td>71</td>
<td>69.9 (12.5)</td>
<td>70.0 (13.0)</td>
<td>66-70</td>
</tr>
<tr>
<td>Gender, male, %</td>
<td>48</td>
<td>48</td>
<td>53</td>
<td>61</td>
<td>63</td>
<td>62</td>
</tr>
<tr>
<td>History of heart failure, %</td>
<td>75</td>
<td>87</td>
<td>65</td>
<td>63</td>
<td>75</td>
<td>64</td>
</tr>
<tr>
<td>Arterial hypertension, %</td>
<td>72.0</td>
<td>71.0</td>
<td>53.0</td>
<td>62.5</td>
<td>61.8</td>
<td>70.2</td>
</tr>
<tr>
<td>Coronary artery disease, %</td>
<td>57.0</td>
<td>50.0</td>
<td>68.0</td>
<td>53.6</td>
<td>50.7</td>
<td>30.7</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>44.0</td>
<td>42.0</td>
<td>27.0</td>
<td>32.8</td>
<td>35.1</td>
<td>45.3</td>
</tr>
<tr>
<td>Atrial fibrillation, %</td>
<td>31.0</td>
<td>31.0</td>
<td>43.0</td>
<td>38.7</td>
<td>43.7</td>
<td>24.4</td>
</tr>
<tr>
<td>Renal dysfunction, %</td>
<td>30.0</td>
<td>30.0</td>
<td>17.0</td>
<td>16.8</td>
<td>26.0</td>
<td>21.4</td>
</tr>
<tr>
<td>COPD, %</td>
<td>31.0</td>
<td>28.0</td>
<td>19.3</td>
<td>11</td>
<td>8</td>
<td>24.8</td>
</tr>
<tr>
<td>Anemia, %</td>
<td>14.7</td>
<td>31.4</td>
<td>14.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADHERE, Acute Decompensated Heart Failure National Registry; AHF, acute heart failure; ALARM-HF, Acute Heart Failure Global Survey of Standard Treatment; COPD, chronic obstructive pulmonary disease; EHFS, EuroHeart Failure Survey; ESC-HF Pilot, European Society of Cardiology-Heart Failure Pilot registry; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; SD, standard deviation.

* Median.

### Table 2
Acute Heart Failure Outcome in Different Registries

<table>
<thead>
<tr>
<th></th>
<th>ADHERE</th>
<th>OPTIMIZE-HF</th>
<th>EHF S I</th>
<th>EHFS II</th>
<th>ESC-HF Pilot (AHF arm)</th>
<th>ALARM-HF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No.</td>
<td>105 388</td>
<td>48 612</td>
<td>11 327</td>
<td>3580</td>
<td>1892</td>
<td>4953</td>
</tr>
<tr>
<td>In-hospital mortality, %</td>
<td>4.0</td>
<td>4.0</td>
<td>6.9</td>
<td>6.7</td>
<td>3.8</td>
<td>11.0</td>
</tr>
<tr>
<td>Hospital stay, median, days</td>
<td>4</td>
<td>4</td>
<td>11</td>
<td>9</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>30-90-days mortality, %</td>
<td>11.2 (30 days)</td>
<td>9.0 (60-90 days)</td>
<td>6.6 (90 days)</td>
<td>36.0 (1 year)</td>
<td>30.0 (60-90 days)</td>
<td>24.0 (90 days)</td>
</tr>
<tr>
<td>1-year mortality, %</td>
<td>36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADHERE, Acute Decompensated Heart Failure National Registry; AHF, acute heart failure; A LARM-HF, Acute Heart Failure Global Survey of Standard Treatment; EHFS, EuroHeart Failure Survey; ESC-HF Pilot, European Society of Cardiology-Heart Failure Pilot registry; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure.
Table 3
Causes and Precipitating Factors of Acute Heart Failure

<table>
<thead>
<tr>
<th>Cardiovascular</th>
<th>Non cardiovascular</th>
<th>Patient-related or iatrogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Acute coronary syndromes</td>
<td>• Infections and febrile states</td>
<td>• Poor compliance with medication</td>
</tr>
<tr>
<td>• Tachycardias (ie, atrial fibrillation)</td>
<td>• COPD exacerbation or asthma</td>
<td>• Increased salt or fluid intake</td>
</tr>
<tr>
<td>• Bradycardias (ie, third degree atrioventricular block)</td>
<td>• Renal dysfunction</td>
<td>• Surgery</td>
</tr>
<tr>
<td>• Uncontrolled hypertension or hypertensive crisis</td>
<td>• Anemia</td>
<td>• Drugs (ie, NSAID, thiazolidinediones)</td>
</tr>
<tr>
<td>• Myocarditis</td>
<td>• Hyperthyroidism</td>
<td>• Alcohol abuse</td>
</tr>
<tr>
<td>• Acute pulmonary embolism</td>
<td>• Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>• Acute valvular regurgitation (ie, endocarditis, myocardial infarction)</td>
<td>• Strenuous exercise</td>
<td></td>
</tr>
<tr>
<td>• Aortic dissection</td>
<td>• Emotional stress</td>
<td></td>
</tr>
<tr>
<td>• Cardiac tamponade</td>
<td>• Pregnancy (peripartum cardiomyopathy)</td>
<td></td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease; NSAID, non-steroid anti-inflammatory drugs.

RISK FACTORS

Several cardiovascular and noncardiovascular conditions may cause a rapid development or deterioration of signs and symptoms of heart failure leading to hospitalization. A detailed list of the causes and precipitating factors leading to AHF is provided in Table 3. Heart failure accounts for less than half of readmission causes. More specifically, according to the EVEREST trial, 46% of patients are admitted because of heart failure, while 39% are hospitalized because of noncardiovascular comorbid conditions.13

A number of clinical and laboratory parameters have been shown to predict AHF hospitalization (Table 4). Gradually aggravating symptoms and signs of congestion, deterioration of biomarkers such as natriuretic peptides or renal function parameters, increasing need for diuretics or intolerance to heart failure medication are the hallmarks of deterioration and thus of an upcoming AHF episode.15

PREVENTION

Primary prevention of AHF concerns the prevention and early diagnosis and treatment of the causes of heart failure (Table 3) and mainly of cardiovascular risk factors and heart disease. Coronary artery disease is the cause in two-thirds of heart failure patients, particularly those with reduced LVEF, while arterial hypertension is found in approximately 70% of patients, particularly those with preserved LVEF.3 Therefore, timely and effective treatment of risk factors for atherosclerosis, coronary artery disease, and arterial hypertension is expected to limit the occurrence of heart failure.

The secondary prevention of AHF concerns the prevention of chronic heart failure decompensation that leads to AHF episodes requiring hospitalization. As each hospitalization for AHF is known to confer additional deterioration of cardiac and kidney function, recurrent AHF episodes lead to a gradual decline of the patient’s clinical course.16 As a result, the greater the number of hospital admissions, the worse patient survival.17 Furthermore, AHF hospitalization represents approximately 70% of the total expenditure on heart failure.18 Therefore, the secondary prevention of AHF episodes represents an important goal both in medical and socioeconomical terms.

As previously stated, a significant proportion of readmissions occur during the first weeks postdischarge.15 It has been postulated that early readmissions are preventable in up to 75% of patients and that the main reasons for early readmissions are incomplete decongestion during the preceding hospital stay and a poor transition plan.19 Therefore, the strategies to prevent readmission mainly concern the optimization of in-hospital management of patients and the development of the patient transition and follow-up plan. These strategies are outlined in Table 5. It should be stressed that patient admission may also provide a chance for implementation or the titration of chronic heart failure therapy, better education, patient training, and the development of a follow-up plan.20

Table 4
Predictors of Postdischarge Rehospitalization for Acute Heart Failure

<table>
<thead>
<tr>
<th>Predictor type</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Increasing body weight, persisting peripheral edema, dyspnea aggravation</td>
</tr>
<tr>
<td>Clinical signs</td>
<td>Increased jugular venous pressure, orthopnea</td>
</tr>
<tr>
<td>Comorbid conditions</td>
<td>Chronic renal disease, diabetes mellitus, COPD, anemia</td>
</tr>
<tr>
<td>Functional status</td>
<td>Quality of life</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>Natriuretic peptides, cardiac troponins, serum sodium, serum creatinine</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>Left ventricular filling pattern</td>
</tr>
<tr>
<td>Treatment</td>
<td>Increase in diuretics, intolerance to disease-modifying therapy with hypotension or renal impairment</td>
</tr>
<tr>
<td>Psychosocial and socioeconomic factors</td>
<td>Living alone, low income</td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease.

Table 5
Strategies to Prevent Postdischarge Rehospitalization for Acute Heart Failure

<table>
<thead>
<tr>
<th>In-hospital treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decongestion</td>
</tr>
<tr>
<td>• Identification and treatment of heart failure cause</td>
</tr>
<tr>
<td>• Treatment and prevention of exacerbating factors</td>
</tr>
<tr>
<td>• Proper titration of chronic heart failure therapy</td>
</tr>
<tr>
<td>Planning and transition</td>
</tr>
<tr>
<td>• Establishment of specific follow-up plan</td>
</tr>
<tr>
<td>• Early postdischarge visit (7–10 days)</td>
</tr>
<tr>
<td>• Collaboration with primary care physician</td>
</tr>
<tr>
<td>• Patient education and training</td>
</tr>
<tr>
<td>• Nurse home visits</td>
</tr>
<tr>
<td>• Telemonitoring</td>
</tr>
</tbody>
</table>
CONFLICT OF INTERESTS

G. Filippatos is a member of steering committees of acute heart failure trials sponsored by Novartis, Cardorents, the European Union and Bayer. J. Parisiis has received fees for conference presentations from Novartis International.

REFERENCES

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.


